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Abstract
 Introduction—The critical role of the tissue microenvironment and B cell receptor (BCR) 
signaling in chronic lymphocytic leukemia (CLL) pathogenesis, and the clinical success of 
targeted agents that disrupt BCR signaling are currently changing the CLL landscape. Three new 
drugs were recently approved for CLL therapy, and other agents are in late development.
 Areas covered—In this review, we summarize data on promising new targeted drugs for 
CLL. The heterogeneous mechanisms of actions of these molecules are described, such as the 
inhibition of BCR signaling, direct targeting of CD20 molecules on the CLL cell surface, and 
BCL-2 inhibition. We present preclinical and clinical data from phase I to III studies in order to 
describe efficacy and side effect profile of these new drugs. Data are derived from peer-reviewed 
articles indexed in PubMed and from abstracts presented at major international meetings.
 Expert opinion—Ibrutinib and idelalisib are challenging the role of chemo-immunotherapy in 
CLL therapy in the frontline and relapsed disease settings. High-risk CLL patients particularly 
benefit from these new agents. Venetoclax and obinutuzumab are other effective agents added to 
our therapeutic armamentarium. Studies to better define the optimal use of these drugs, alone, or 
rather in combination or sequenced are underway.
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 1 Introduction
The therapeutic landscape in chronic lymphocytic leukemia (CLL) has considerably changed 
over the past few years. Prior to that, patients with CLL were treated with chemotherapy 
(alkylating agents, i.e. cyclophosphamide, chlorambucil, and purine analogues, i.e. 
fludarabine) without any major impact on the overall disease outcome. In contrast, the 
addition of the anti-CD20 monoclonal antibody (mAb) rituximab to the combination of 
fludarabine and cyclophosphamide (FCR) as chemo-immunotherapy[1] induced higher 
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overall response rates (ORR), longer progression-free survival (PFS) and longer overall 
survival (OS) when compared to fludarabine and cyclophosphamide chemotherapy alone[2]. 
The median PFS in CLL8 trial for patients receiving FCR was 4.8 years, although a longer 
median PFS of 6–7 years was reported in a phase II trial conducted at The University of 
Texas MD Anderson Cancer Center[2, 3], and FCR regimen is currently considered standard 
frontline treatment for young fit patients with CLL. Nevertheless, the majority of patients 
with CLL, due to age, comorbidity, or presence of high-risk disease features [unmutated 
IGHV, del(17p)], are not well suited for this treatment modality.
Significant progress in the understanding of CLL biology recently led to the identification of 
a series of new molecules that can more specifically target CLL cells. These new drugs are 
now approved or in a late stages of clinical development, and some of them are already 
considered of first choice for selected patients as per international guidelines[4]. The 
mechanism of action and target effects of these drugs are depicted in Table 1, whereas key 
clinical data are summarized in Table 2.
 2 Bruton tyrosine kinase (BTK) inhibitors
The B cell receptor (BCR) is a transmembrane receptor expressed on the cell membrane of 
B cells. The binding of a specific antigen to the BCR triggers the activation of a cascade of 
intracellular signaling molecules, which are essential for normal B-cell development, 
survival, and proliferation, but are also involved in CLL pathogenesis, where they function 
in a similar fashion, promoting CLL cell survival and expansion[5, 6]. Antigen binding to 
the BCR leads to the recruitment of Lyn and Syk tyrosine kinases, which subsequently 
activate BTK[7]. BTK is named after Dr. Ogden Bruton, a pediatrician who described in 
1952 the first case of Bruton’s agammaglobulinemia (X-linked agammaglobulinemia), a rare 
congenital immunodeficiency caused by missense mutations in the BTK gene, resulting in 
agammaglobulinemia and lack of mature B cells[8]. BCR signaling in CLL patients is 
characteristically activated in secondary lymphatic tissues[9], where CLL cells can 
encounter auto-antigens and microbial antigens[10] and where the CLL cells proliferate in a 
BCR signaling-dependent fashion in areas called “proliferation centers” or “pseudo-
follicles”. BCR crosslinking with BCR-intrinsic motifs, termed autonomous BCR signaling, 
has been proposed as an additional alternative mechanism for BCR pathway activation[11]. 
BTK in turn activates downstream targets including phospholipase Cγ2 (PLCγ2) and 
NFκB[12].
 2.1 Ibrutinib
 2.1.1 Ibrutinib mechanism of action—Ibrutinib (PCI-32765) is an orally available 
small molecule inhibitor that covalently bonds with BTK at the C481 residue. This binding 
leads to an irreversible inhibition that hinders the kinase activity and results in a blockade of 
downstream signaling in vitro and in vivo. As a result, ibrutinib inhibits BCR signaling and 
consequently BCR signaling-dependent proliferation and survival of CLL cells[13–15]. In 
addition to its effects on BCR signaling, ibrutinib also inhibits the signaling of other cell 
surface receptors, including chemokine receptors and adhesion molecules which regulate the 
migration of CLL cells in response to chemotactic factors (chemotaxis) and their adhesion. 
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These effects on CLL tissue-homing and –retention mechanisms contribute to the 
characteristic clinical activity of ibrutinib and related kinase inhibitors, which cause 
redistribution of tissue-resident CLL cells into the peripheral blood, resulting in a transient 
increase in peripheral blood leukemia cell counts during the first months of treatment.
Ibrutinib also inhibits the BCR signaling-dependent secretion of CCL3/CCL4 by CLL 
cells[15], which normally function as CLL cell-derived chemo-attractants to recruit T cells 
and monocytes to sites of activated and proliferating CLL cells within the tissues. Finally, 
ibrutinib significantly delays disease progression in preclinical mouse models of CLL[15–
17].
 2.1.2 Ibrutinib in clinical trials—The activity of ibrutinib was first shown in a phase I 
trial that enrolled 16 relapsed/refractory patients with CLL (over a total of 56 patients with 
various B-cell malignancies)[18]. Different dose regimens were tested and the dose 
escalation could proceed up to 12.5 mg/kg per day without reaching any dose limiting 
toxicities. However, lower doses (2.5 mg/kg per day) were sufficient to obtain full 
occupancy of the BTK enzyme. The reported ORR was 54% for the entire patient 
population, and 69% for the CLL cohort. Based on the promising efficacy and safety data 
from this trial, a multi-center phase Ib/II clinical trial was conducted in 85 heavily pretreated 
patients with relapsed/refractory CLL or small lymphcytic lymphoma (SLL)[19]. Two 
different dose cohorts were studied (continuous daily dose of 420 mg or 840 mg), and after a 
median follow-up of 20.9 months the ORR was 71% (CR 3%; partial response, PR 68%). 
The response was superimposable in the two dose cohorts. Notably, the ORR increased to 
90% at a longer follow-up of 3 years[20]. Based on the characteristic response pattern a new 
response category was defined for patients meeting the requirements for PR according to 
2008 IWCLL criteria[21], but having persistent lymphocytosis (PR with persistent 
lymphocytosis, PRL; 20% in the 420 mg cohort and 15% in the 840 mg cohort). Importantly, 
responses were observed independently from the presence of high-risk prognostic factors. 
For example, patients with del(17p) achieved an ORR of 68%, with a 26-month estimated 
rate of PFS of 57%, comparing extremely favorable with historical data for patients with the 
same negative prognostic profile, even when treated frontline with conventional 
chemoimmunotherapy[2, 22]. Most reported adverse events (AE) were grade 1 or 2. Grade 
1–2 AE occurring in >20% of patients were: diarrhea, upper-respiratory tract infection, 
fatigue, cough, arthralgia, rash, pyrexia, and edema, and muscle spasm. The most common 
grade ≥3 AE were pneumonia (10 patients, 12%) and dehydration (5 patients, 6%). Four 
cases of grade 3–4 bleeding events were reported, and therefore patients taking warfarin 
were excluded from the subsequent trials. The bleeding occurrence in patients treated with 
ibrutinib might be an on-target effect, given the role of BTK in platelet aggregation[23], and 
the activity of ibrutinib in inhibiting collagen and von Willebrand factor-dependent platelet 
adhesion and aggregation[24, 25].
Ibrutinib was also tested as frontline therapy in older patients (≥65 years)[26], resulting in an 
ORR of 71%, with 4 patients (13%) achieving a CR. The estimated 2-year PFS was 96.3%, 
and 2 year OS was 96.6%. The durability of responses to ibrutinib in treatment-naïve and 
relapsed/refractory patients with CLL or SLL was confirmed in a recent study update of the 
two original trial cohorts after a median follow-up of 3 years[20]. Median PFS was not 
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reached for both groups of patients. The estimated PFS rate at 30 months was 96% for 
untreated patients, and 69% for relapsed/refractory patients. Progression events occurred 
mainly in relapsed patients with del(17p). The mechanisms leading to the loss of response to 
ibrutinib are not fully understood, but ibrutinib resistance has been associated in several 
cases with point mutations in BTK at the ibrutinib binding site and in the downstream 
signaling molecule PLCγ2[27], resulting in impaired ibrutinib binding or enhanced 
downstram signaling, respectively.
Ibrutinib was compared to ofatumumab in a phase III randomized trial (RESONATE) in 391 
patients with relapsed/refractory CLL who were considered inappropriate for treatment with 
purine analogues[28]. Although in part expected based on the data on ofatumumab efficacy 
in CLL (58% ORR and median PFS of 5.7 months in patients refractory to fludarabine and 
alemtuzumab[29]), it was an important reassurance that patients treated with ibrutinib had 
significantly higher response rates (63% vs 4%) and longer median PFS (not reached vs 8.4 
months after a median follow-up of 9.4 months). Importantly, the study also demonstrated a 
survival advantage for ibrutinib-treated patients (one-year OS 90% vs 81%; HR for death 
0.43, 95% CI 0.24–0.79; p=0.005). The significant difference in efficacy between the two 
drugs was also observed in the cohort of patients carrying del(17p), and in patients resistant 
to purine analogues. AE reported in ≥20% of patients in the ibrutinib arm were diarrhea, 
fatigue, pyrexia, and nausea. The incidence of AE was higher in the ibrutinib arm generally 
due to longer drug exposure, and specific ibrutinib-related signals were higher incidence of 
atrial fibrillation (3% vs 0%), milder (but not severe) bleeding events, and cataracts (3% vs 
1%).
The RESONATE-2 trial randomly assigned 269 elderly untreated patients with CLL or SLL 
to receive either ibrutinib or chlorambucil[30]. Patients with a known del(17p) were 
excluded from this study. Treatment with ibrutinib induced a significantly higher rate of 
response (ORR including PRL 88% vs 35%), a longer median PFS (not reached vs 18.9 
months), and a longer OS (98% vs 85% at 2 years). All grade AE reported in ≥20% of 
patients in the ibrutinib arm were diarrhea (42% vs 17%), fatigue (30% vs 38%), cough 
(22% vs 15%), and nausea (22% vs 39%). Main grade 3–4 AE in the ibrutinib arm were 
neutropenia (10% vs 18%), anemia (6% vs 8%), hypertension (4% vs 0%), and diarrhea (4% 
vs 0%). In 4% of patients treated with ibrutinib a major hemorrhage was observed (no fatal 
events), and 6% developed atrial fibrillation (75% grade 2).
In a recently published single-arm phase II study, ibrutinib was specifically evaluated in 35 
previously untreated and 16 relapsed/refractory CLL patients with del(17p) or TP53 
aberrations[31]. Responses (including PRL) were observed in 97% of untreated patients and 
in 80% of relapsed/refractory patients after a median follow-up of 2 years.
Based on all these results, ibrutinib was approved in the US and in Europe for the treatment 
of patients with relapsed CLL, and for treatment-naïve patients carrying a del(17p) or a 
TP53 mutation.
Combination studies were also designed to potentially increase the response rate and 
prolong the response duration, especially in patients considered to be at high risk of relapse 
Vitale and Burger Page 4
Expert Opin Pharmacother. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
or progression. In fact, it has been shown that patients who progress after responding to 
ibrutinib therapy, which generally are heavily pre-treated high-risk patients, often with 
del(17p), have a very poor prognosis[32, 33].
Ibrutinib in association with rituximab was studied in a phase II study in 40 patients with 
high-risk CLL based on presence of unfavorable cytogenetic abnormalities [del(17p), TP53 
mutation, or del(11q)] or a short PFS <36 months after previous first-line chemo-
immunotherapy. The ORR was 95% with the ibrutinib-rituximab combination, with 8% of 
patients achieving a CR. The PFS at 18 months was 78% in all patients, and 72% in those 
with del(17p) or TP53 mutation. The therapy was overall well tolerated and the most 
common adverse events were respiratory infections[34].
The combination of ibrutinib with chemo-immunotherapy is also under investigation, and 
the results of a small-scale phase Ib study exploring safety and efficacy of ibrutinib in 
association with FCR or bendamustine and rituximab (BR) in relapsed/refractory patients 
have been recently published[35]. BR-ibrutinib induced an ORR of 93%, including 17% CR 
(which increased to 40% with longer follow-up). PFS at 36 months was 70%. All 3 patients 
treated with ibrutinib-FCR achieved CR. As expected, the spectrum of AE recapitulates that 
of ibrutinib and chemo-immunotherapy, when used individually.
Ibrutinib combined with BR was recently compared with BR + placebo in an international, 
double-blind, placebo-controlled, phase III study (HELIOS) for relapsed/refractory patients 
with CLL or SLL[36]. A total of 578 patients were enrolled and patients with del(17p) or 
with CLL considered refractory to bendamustine were excluded. The ORR was significantly 
higher in the ibrutinib cohort compared to the placebo cohort (83% vs 68%). CR/CRi were 
achieved in 10% of patients in the ibrutinib group and in 3% of patients in the placebo 
group, and in the intention-to-treat population minimal residual disease (MRD) negative 
patients accounted for 13% and 5% in the ibrutinib and placebo group, respectively. The 
addition of ibrutinib significantly prolonged the median PFS (not reached vs 13.3 months, at 
a median follow-up of 17 months). The most frequent all-grade AE were neutropenia (59% 
and 55% in the ibrutinib and placebo group, respectively), nausea (38% and 36% in the 
ibrutinib and placebo group, respectively), and diarrhea (35% and 21% in the ibrutinib and 
placebo group, respectively). The overall proportion of patients with AE of grade 3–4 was 
similar between the two treatment groups (77% in the ibrutinib group and 74% in the 
placebo group). The most common grade 3–4 AE in both groups were neutropenia (54% and 
51% in the ibrutinib and placebo group, respectively), and thrombocytopenia (15% in both 
groups). Overall, the safety profile was similar to that previously reported with ibrutinib and 
BR individually.
 2.2 Acalabrutinib
Acalabrutinib (ACP-196) is a second generation BTK inhibitor which shares with ibrutinib 
the same mechanism of action, but has been designed to be a more potent and selective 
inhibitor of BTK, therefore potentially avoiding off-target side effects. The results of a phase 
I/II study exploring the safety and efficacy of oral acalabrutinib have been recently 
published[37]. A total of 61 patients with relapsed CLL were treated showing a favorable 
toxicity profile, the most common AE were headache (43% overall, 0% grade 3–4), weight 
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gain (26% overall, 2% grade 3–4), pyrexia (23% overall, 3% grade 3–4), and upper 
respiratory tract infections (23% overall, 0% grade 3–4). The reported ORR was 95% (85% 
PR and 10% PRL) for the entire patient population, and 100% (89% PR and 11% PRL) for 
the del(17p) cohort. The drug is further developed in ongoing phase III trials, one comparing 
acalabrutinib versus ibrutinib in relapsed/refractory CLL patients with high risk disease 
features (NCT02477696), and another comparing obinutuzumab + chlorambucil versus 
obinutuzumab + acalabrutinib versus acalabrutinib monotherapy in treatment-naïve CLL 
patients (NCT02475681).
 3 Phosphatidylinositol-3-kinase inhibitors
Phosphatidylinositol-3-kinase (PI3K) is another cytoplasmic tyrosine kinase involved in the 
signaling pathway downstream of the BCR (and other surface receptors). After the 
phosphorylation of cytoplasmic domains of CD19 by Lyn, PI3K is recruited and activated, 
generating a lipid second messenger molecule, phosphatidylinositol-(3,4,5)-triphosphate 
(PIP3). Subsequently, other downstream signaling proteins are recruited and activated 
including phosphatidylinositol-dependent kinase 1 (PDK1)[7]. PIP3 is essential for BTK 
recruitment and PLCγ2 activation, therefore linking PI3K function with Ca2+ signaling[38]. 
Downstream, the activation of signaling pathways dependent on Akt and mammalian target 
of rapamycin (mTOR) influences cell metabolism, proliferation, DNA repair, survival, 
cytoskeleton changes and migration[7, 39]. PI3Ks are classified into three classes (I, II, III), 
and class I is further composed by four different isoforms (α, β, γ, δ). Isoforms α and β are 
widely expressed in many tissues, whereas isoforms γ and δ are restricted to hematopoietic 
cells. PI3Kδ is the form predominantly expressed by hematopoietic cells and plays a critical 
role in B cell homeostasis and function[39]. The knockout of the PI3Kδ gene in mouse 
models leads to B-cell deficiency, confirming the critical role of this signaling molecule in 
B-cell development and function[40, 41]. Moreover, PI3Kδ signaling pathway has been 
shown to be dysregulated in many solid cancers and is constitutively active in CLL[42, 43].
 3.1 Idelalisib
 3.1.1 Idelalisib mechanism of action—Idelalisib (GS-1101, CAL-101) is an orally 
available reversible inhibitor of the δ isoform of PI3K, causing a decrease in phosphorylation 
of several downstream targets including Akt. The effect of the interruption of the BCR 
signaling pathway is a disruption of the interactions between CLL cells and tumor 
microenvironment, as well as direct induction of leukemia cell apoptosis[44, 45].
 3.1.2 Idelalisib in clinical trials—Idelalisib was initially evaluated in a phase I trial in 
54 patients with relapsed/refractory CLL with adverse clinical and biological features[46]. 
Patients were treated for 48 weeks with daily idelalisib given continuously at different dose 
regimens (50 mg bid, 100 mg bid, 300 mg qd, 150 mg bid, 200 mg bid, 350 mg bid). The 
observed ORR was 72%, with 39% of patients achieving a PR and 33% achieving a PRL. 
The identified optimal dose was 150 mg twice daily, with a median PFS for patients 
receiving this dose or higher of 32 months, compared with 7 months for those receiving 
lower doses. The median OS was not reached, with 75% of patients surviving at 36 months. 
Thirteen patients had a del(17p) and the ORR in this group was 58%, with a median PFS of 
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3 months. Frequently reported AE included: fatigue (32%), diarrhea (48%), pyrexia (32%), 
cough (29%), back-pain (22%) and transaminase elevation (28%). Sixty-seven% of patients 
experienced a serious AE (mainly related to infectious complications) and 13% discontinued 
therapy due to an AE. Unexpected non-infectious serious AE included colitis (5.6%) and 
interstitial pneumonitis (1.9%).
The results of a phase III randomized trial comparing the activity of idelalisib (150 mg bid) 
in combination with rituximab vs placebo + rituximab were recently published[47]. The trial 
enrolled 220 patients with relapsed CLL who had progressed within 24 months of their last 
treatment, had previously received at least one treatment regimen including an anti-CD20 
mAb or two or more cytotoxic regimens, and were deemed not eligible to receive cytotoxic 
chemotherapy (due to significant myelosuppression, a creatinine clearance of <60 ml/min or 
a cumulative illness rating scale [CIRS] >6). Patients in both treatment arms received 8 
doses of rituximab, and patients on placebo were eligible to crossover and receive idelalisib 
if disease progression occurred. For 176 evaluable patients (88 in each arm) the ORR was 
significantly higher in patients receiving idelalisib (81% vs 13%, p<0.001). All responders 
had a PR. The response rate of the combination of idelalisib and rituximab was not affected 
by del(17p) or TP53 and IGHV mutational status. Patients in the idelalisib arm also had a 
prolonged PFS (93% vs 46% at 24 weeks; HR 0.15, 95% CI 0.08–0.28), and improved OS 
(92% vs 80% at 1 year; HR 0.28, 95% CI 0.09–0.86). Similar AE rates were reported in the 
two treatment arms. In the idelalisib arm, the five most common reported AE were pyrexia, 
fatigue, nausea, chills, and diarrhea. A grade 3 or greater elevation of hepatic transaminases 
occurred in 6% of patients, although it was not the reason for treatment discontinuation. 
Serious diarrhea and pneumonitis were more frequent in the idelalisib arm, but overall the 
treatment discontinuation rates were comparable between the two groups (8% vs 10% in the 
idelalisib and placebo groups, respectively). Gastrointestinal and skin disorders were the 
most common reasons for discontinuation in the idelalisib group. Due to the exceedingly 
favorable results observed in the idelalisib + rituximab arm, the trial was stopped early and 
idelalisib was approved, in combination with rituximab, in the US for the treatment of 
relapsed/refractory CLL patients, and in Europe for patients with relapsed/refractory disease 
or treatment-naïve with del(17p) or TP53 mutation and not candidate for chemo-
immunotherapy.
The results obtained by idelalisib in combination with rituximab in treatment-naïve older 
(median age 71) patients have also been reported[48]. The ORR was 97% (including 19% 
CR), and PFS at 36 months was 83%. The side effect profile of this treatment combination is 
very characteristic, with a reported rate of grade 3–4 diarrhea/colitis of 42%, grade 3–4 
AST/ALT elevation of 23%, grade 3–4 pneumonia of 19%, and grade 3–4 rash of 13%.
Recently, higher rates of AE were reported in a phase II study of idelalisib in combination 
with ofatumumab in previously untreated patients with CLL (n=21)[49]. Grade 3–4 
transaminitis was observed in 57% of patients, grade 3–4 enterocolitis in 14%, and grade 3–
4 pneumonitis in 10%. Preclinical data and responsiveness to corticosteroids suggest an 
autoimmune etiology, and the association with younger age and higher absolute lymphocyte 
counts at baseline may recommend the need to formulate better selection criteria for patients 
treated with this agent in the frontline setting.
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Preliminary results of the combination of idelalisib with BR compared with BR + placebo 
have been recently presented[50]. This phase III, randomized, placebo-controlled study 
enrolled 416 patients with relapsed/refractory CLL and showed a significantly improved 
median PFS in the experimental arm when compared to the placebo arm (23 vs 11 months). 
The median OS was not reached in either cohort, but the HR for survival was statistically 
significant (HR=0.55; p-value 0.008; 95% CI 0.36–0.86). Grade 3–4 diarrhea was reported 
in 7.2% of patients in the idelalisib arm (vs 1.9% in the placebo arm) and incidence of 
serious AE pneumonitis was 1.4% (vs 0%). Transaminase abnormalities were observed more 
frequently in the idelalisib arm (any grade ALT 59.9% vs 30.6%, any grade AST 52.2% vs 
27.8%, grade 3–4 ALT 21.3% vs 2.9%, grade 3–4 AST 15.5% vs 3.3%).
 3.2 Duvelisib
 3.2.1 Duvelisib mechanism of action—Duvelisib (IPI-145) is an oral small-
molecule that potently inhibits both PI3K3γ and PI3Kδ isoforms. It was initially developed 
to suppress the activity of different components of adaptive and innate immunity in 
autoimmune and inflammatory diseases[51]. Due to its effect in suppressing B cell 
proliferation, it is now also under investigation for the treatment of lymphoproliferative 
diseases. Ideally, the inhibition of both PI3K isoforms could achieve a broader inhibitory 
activity and enhanced efficacy[51]. In vitro studies confirmed both the activity of duvelisib 
in inducing apoptosis in primary CLL cells, including samples with poor prognostic 
markers, and its safety towards normal B and T lymphocytes[52].
 3.2.2 Duvelisib in clinical trials—Preliminary results of an ongoing phase I trial with 
duvelisib in patients with relapsed/refractory CLL have been presented[53]. Duvelisib at a 
dose of 25 mg twice daily provided an optimal biologic effect (maximum pAKT inhibition 
in CLL cells, reduction in serum cytokines and chemokines, reduction in CLL cell 
proliferation index). ORR was 55% (n=49), including 1 CR and 26 PR, and it was similar 
irrespective of dose, or the presence of del(17p) or TP53 mutation. 83% of patients (38/46) 
achieved >50% reduction in lymphadenopathy by CT scan. Treatment emergent AE were 
similar across the dose range. The most common AE grade ≥3 were neutropenia (31%), 
thrombocytopenia (11%), febrile neutropenia (15%), and pneumonia (11%) (median of 7.3 
treatment cycles, range 1.0–30.8).
Different studies evaluating the activity of duvelisib in combination with chemo-
immunotherapy are currently recruiting patients (e.g. NCT02158091, NCT01871675). 
Moreover, a phase III study to compare duvelisib monotherapy (starting dose: 25 mg twice 
daily) versus ofatumumab is ongoing (NCT02004522).
 4 BH3 mimetic compounds
The BCL-2 family of proteins are important regulators of the intrinsic apoptosis pathway, 
which integrates stress and survival signals and governs cell survival and death[54, 55]. The 
BCL-2 oncogene was first identified in follicular lymphoma, where the encoded protein is 
overexpressed as a result of the t(14;18)[56], but BCL-2 overexpression is also a contributor 
in the pathogenesis other lymphoid malignancies. In CLL the high expression of BCL-2 has 
been linked to the deletion or downregulation of microRNAs miR15a and miR16-1[57].
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This understanding led to the development of BH3 mimetic compounds that mimic the 
action of the BH3-only proteins, which are the natural antagonists of anti-apoptotic members 
of the BCL-2 family (reviewed in[58]). The first tested molecule was navitoclax (ABT-263), 
an orally bioavailable small molecule with an inhibitory activity on both BCL-2 and BCL-
XL. It was initially studied for the treatment of CLL[59], but drug development later was 
abandoned due to toxicity, primarily thrombocytopenia.
 4.1 Venetoclax
 4.1.1 Venetoclax mechanism of action—Venetoclax (ABT-199, GDC-0199) is an 
orally available small molecule that binds with high affinity to BCL-2 and with low affinity 
to other BCL-2 family proteins (i.e. BCL-XL and BCL-W)[60]. Pivotal data showed that 
venetoclax has promising in vitro tumor cell killing activity, induces the regression of 
hematological tumors in murine models, and has reduced toxicity on platelets both ex vivo 
and in vivo compared to navitoclax[60].
 4.1.2 Venetoclax in clinical trials—As of March 2016, venetoclax has not yet been 
approved for clinical use, but it is currently being tested in late-stage clinical trials for CLL. 
Preliminary results published for the first three patients with refractory CLL treated in the 
first-in-human clinical trial showed that a single dose of ABT-199 induced rapid tumor lysis 
and confirmed that specific BCL-2 inhibition is a valid approach for CLL therapy[60].
Venetoclax was evaluated as single agent in a phase I study for the treatment of high risk 
relapsed/refractory CLL and SLL[61]. After a dose-escalation phase in which patients 
received venetoclax ranging from 150 to 1200 mg/day (n=56), an expansion cohort was 
treated at a dose of 400 mg/day (n=60), based on balance of overall response and safety data. 
A stepwise intra-patient increase in dose (ramp-up) to the final dose was implemented due to 
the early events of tumor lysis syndrome. After a median follow-up of 17 months, the ORR 
was 79%, with a 20% CR and a 5% of MRD negative CR. In the dose-escalation cohort the 
median PFS was 25 months, whereas this data cannot be reliably estimated in the expansion 
cohort due to the short follow-up in this group. The 15-months PFS was estimated to be 66% 
(95% CI, 51 to 77). Patients carrying a del(17p) had a median PFS of 16 months (95% CI, 
11 to 25). Tumor lysis syndrome occurred in 18% of patients in the dose-escalation cohort 
(clinical tumor lysis syndrome in 3 patients, laboratory-only tumor lysis syndrome in 7 
patients). Two patients with clinical tumor lysis syndrome had severe sequelae, including 
one death. In the expansion cohort, only one patient had laboratory evidence of tumor lysis 
syndrome. In the entire patient group, most common AE were diarrhea (52%), upper 
respiratory tract infection (48%), nausea (47%), neutropenia (45%), and fatigue (40%). Most 
common grade 3–4 AE were neutropenia (41%), anemia (12%), and thrombocytopenia 
(12%).
Venetoclax in combination with rituximab was studied in a phase Ib trial in relapsed/
refractory CLL patients[62]. Rituximab was added after the completion of the ramp-up 
phase and preliminary pharmacokinetic data suggested a negligible effect of rituximab on 
venetoclax exposure[63]. Of 49 patients evaluable for response, the ORR was 86% (CR/CRi 
41%, nPR 2%, PR 43%). MRD on bone marrow was quantified in 40 patients and MRD-
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negativity was achieved in 75% of patients who achieved a CR/CRi. Overall 26 patients 
(53% of the total) achieved MRD-negativity. At a median follow-up of 17.5 months, the 
median PFS has not been reached. Twelve-month and 24-month PFS is 87% and 84%, 
respectively, and 12-month OS is 94%. The most common treatment-emergent AE were 
neutropenia (55%), diarrhea (53%), nausea (49%), upper respiratory tract infection (45%), 
fatigue and pyrexia (each 37%), cough (35%), and headache (33%). The most common 
overall grade 3–4 AE were neutropenia (53%), thrombocytopenia (16%), anemia (14%), 
febrile neutropenia (12%), and leukopenia (10%). One death due to tumor lysis syndrome 
was reported. More mature results have yet to be published, but based on these preliminary 
promising data different phase II and III trials have been started to evaluate the efficacy of 
venetoclax alone or in combination with chemo-immunotherapy (e.g. NCT01671904, 
NCT01685892, NCT02427451, NCT02005471, NCT02242942).
 5 Novel anti-CD20 mAb
CD20 is a transmembrane protein broadly expressed on the surface of normal and malignant 
B lymphocytes, with an incompletely understood physiologic role. The targeting of the 
CD20 molecule with specific mAb has dramatically improved outcomes B-cell 
lymphoproliferative diseases, including CLL[64]. Rituximab and ofatumumab are 
categorized as type I antibodies, and their cytotoxic activity is mainly dependent on 
complement activation[65]. They are currently widely used in CLL in combination with 
purine analogues and alkylating agents, whereas their efficacy as single agents is modest.
 5.1 Obinutuzumab
 5.1.1 Obinutuzumab mechanism of action—As opposed to type I, type II 
antibodies characteristically stimulate antibody-dependent cell-mediated cytotoxicity 
(ADCC)[65]. Obinutuzumab (GA101) is a fully-humanized type II IgG1 mAb that binds to 
the same epitope as rituximab, but has a unique glycoengineered Fc region which was 
designed to have a stronger binding affinity with effector cells[66]. Preclinical in vitro data 
confirmed an increased direct cell death and effector cell-dependent cytotoxicity induced by 
obinutuzumab, when compared to rituximab[66, 67].
 5.1.2 Obinutuzumab in clinical trials—Initial phase I studies showed the activity of 
obinutuzumab as single agent in patients with different B-cell lymphomas[68, 69]. In the 
phase I/II GAUGUIN trial, single agent obinutuzumab was administered to 33 heavily 
pretreated relapsed/refractory CLL patients[70]. ORR was 62% in the phase I cohort (n=13) 
and 15% in the phase II cohort (n=20), with no CRs. The difference in response between the 
two cohorts was attributed to an imbalance in tumor burden (based on the sum of the 6 
largest lymph nodes). Median PFS in the phase II cohort was 10.7 months and median 
duration of response was 8.9 months. Infusion-related reactions occurred in almost all 
patients but the majority were grade 1–2. Neutropenia grade 3–4 was reported in 54% and 
20% of patients in phase I and II, respectively. Obinutuzumab was studied as frontline 
treatment in CLL patients with significant comorbidities (Cumulative Illness Rating Scale, 
CIRS, score >6 and/or creatinine clearance <70 mL/min) in a recent phase III study from the 
German CLL Study Group (GCLLSG)[71]. The study compared 3 treatment arms: 
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chlorambucil alone vs chlorambucil + rituximab (R-chlorambucil) vs chlorambucil + 
obinutuzumab (G- chlorambucil). The ORR and CR were higher in patients treated with G- 
chlorambucil as compared to the other arms (ORR: G- chlorambucil 77.3%, R- chlorambucil 
65.7%, chlorambucil 31.4%; CR: G- chlorambucil 22.3%, R- chlorambucil 7.3%, 
chlorambucil 0%). The negativity of MRD was also evaluated as parameter of response, and 
the rate resulted higher in the obinutuzumab group compared with the rituximab group (bone 
marrow: G- chlorambucil 19.5% vs R- chlorambucil 2.6%; blood: G- chlorambucil 37.7% vs 
R- chlorambucil 3.3%). The addition of obinutuzumab significantly prolonged PFS 
compared with the other two groups (median PFS: G- chlorambucil 26.7 months, R- 
chlorambucil 15.2 months, chlorambucil 11.1 months), and this difference was seen in all 
patient subgroups, except for del(17p). An OS advantage was seen for patients treated with 
G- chlorambucil compared to those treated with chlorambucil alone (HR for death 0.41, 
95% CI 0.23–0.74, p=0.002), but no significant OS difference was demonstrated between 
the rituximab and obinutuzumab containing groups. The obinutuzumab arm was 
characterized by a higher incidence grade 3–4 infusion-related reactions (20% during the 
first infusion, 0% during subsequent infusions), grade 3–4 thrombocytopenia (10%) and 
grade 3–4 neutropenia (10%), with no increase in the risk of infection in the obinutuzumab 
group. Based on the results of this study, obinutuzumab is now approved in the US and 
Europe for the treatment of previously untreated co-morbid CLL patients in combination 
with chlorambucil.
Obinutuzumab was also studied in combination with different chemotherapy agents. The 
phase Ib GALTON trial evaluated obinutuzumab in association with fludarabine and 
cyclophosphamide (G-FC, n=21) or bendamustine (G-B, n=20) in previously untreated fit 
CLL patients[72]. The ORR for the G-FC group was 62% (10% CR; 14% CRi), whereas it 
was 90% (20% CR, 25% CRi) in the G-B arm. No relapses or deaths were observed after a 
median follow-up of 20.7 months in the G-FC cohort, and 23.5 months in the G-B cohort. 
The main grade 3–4 AE were: neutropenia (G-FC 29%, G-B 50%), febrile neutropenia (G-
FC 19%, G-B 10%), thrombocytopenia (G-FC 19%, G-B 10%), infections (G-FC 19%, G-B 
5%), infusion-related reactions (G-FC 29%, G-B 10%, all grade 3–4 infusion-related 
reactions were at first obinutuzumab infusion).
 6 Conclusion
New treatment options are now available for patients with CLL, and other drugs are 
currently in a late stage of development. The BCR signaling pathway can be targeted by 
BTK inhibitors (i.e. ibrutinib, acalabrutinib), or by PI3K inhibitors (i.e. idelalisib, duvelisib). 
Another important therapeutic target is BCL-2, which is inhibited by venetoclax. Moreover, 
a novel glycoengineered type II anti-CD20 mAb (obinutuzumab) has recently been 
approved. The majority of these drugs are administered orally, and their mechanism of 
action is novel and entirely different when compared to standard chemo-immunotherapy. 
The clinical data with the novel agents are highly promising, but the impact of these drugs 
on the long term outcome of patients with CLL still needs to be better defined. Today, the 
new drugs already have had a major impact on outcome in CLL patients with high-risk 
disease who characteristically have poor outcome with chemo-immunotherapy; many of 
these patients now have durable responses on ibrutinib- or idelalisib-based regimen.
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 7 Expert opinion
Novel agents recently approved for the treatment of CLL (ibrutinib, idelalisib, 
obinutuzumab) offer new options that already impact patients’ outcome, especially in CLL 
patients with high-risk disease (del(17p) or TP53 mutations, unmutated IGHV). In addition 
to these approved drugs, several other new molecules, which currently are tested in advanced 
stage clinical trials, likely will become available in the near future. These developments are 
highly promising, because more choices and more effective therapy for high-risk patients - 
who characteristically have inferior responses to chemo-immunotherapy - will improve the 
outcome of patients suffering from this leukemia. Nonetheless, the new agents also increase 
the complexity of CLL treatment algorithm, and many questions still remain unanswered 
about the optimal use of these agents in CLL.
Among the most exciting innovations related to these agents have been new important 
lessons about disease biology derived from clinical and translational studies. By interfering 
with the BCR signaling pathway, ibrutinib and idelalisib (and the second generation 
molecules) interfere with critical survival and growth circuits within the CLL cell clone, but 
they also disrupt the leukemia-promoting interactions (“cross talk”) between CLL cells and 
their tissue microenvironment. While already recognized prior to the use of ibrutinib and 
idelalisib, the success of the BCR signaling inhibitors now corroborates with solid clinical 
evidence the importance of the tissue microenvironment, chemokines and their receptors, 
and the BCR as central regulators in CLL pathogenesis. Redistribution of CLL cells from 
tissue sites into the peripheral blood, causing rapid shrinkage of enlarged nodes, and at the 
same time a transient increase of leukemia cell counts in the peripheral blood, which then 
over time undergo death “by neglect”, as they are removed from their nurturing 
microenvironment, is a class effect of the kinase inhibitors that primarily target BCR 
signaling. This phenomenon is immediately reversible and dependent on continuous 
presence of the inhibitor, and demonstrates the relevance of CLL cell recirculation between 
blood and tissues as part of the disease process. Notably, it has been shown that prolonged 
lymphocytosis is not associated with adverse outcomes after ibrutinib therapy[73]. There are 
currently no reported cases of ibrutinib-induced leukostasis, and leukapheresis is still not 
indicated in patients with CLL, however it is prudent to closely monitor patients with a high 
number of circulating lymphocytes to promptly detect signs and symptoms of leukostasis. 
Regarding the response evaluation, the need of new guidelines has been suggested[74], 
considering that lymphocytosis in the absence of other signs of disease progression should 
not be regarded as an indication of treatment failure.
Achievement of deep remissions with MRD-negativity after chemo-immunotherapy 
correlates with improved PFS and OS in CLL[75] and has traditionally been the ultimate 
goal of therapy. Long term follow-up of the original 300 patients treated with FCR at MD 
Anderson Cancer Center[76] showed a PFS of 53.9% at 12.8 years for patients with mutated 
IGHV, with a plateau on the PFS curve, and confirmed that MRD-negativity is highly 
predictive of long-term PFS after FCR therapy, particularly in patients with mutated IGHV. 
In contrast, responses to ibrutinib and idelalisib occur at a slower pace than with chemo-
immunotherapy, and many patients who experience partial response may achieve durable 
responses with long-term disease control, or eventually CRs after longer treatment with 
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these kinase inhibitors. It is currently unclear whether the depth of remission translates into 
longer disease-free survival when treating with ibrutinib, idelalisib, and the related 
compounds. Venetoclax, in contrast to ibrutinib and idelalisib, can induce MRD-negativity 
in a larger proportion of patients, but it is unclear at this time whether this potential 
advantage translates into longer PFS. Therefore, it is expected that the clinical use and the 
relevance of MRD assessment will be adapted over the next few years, and probably will be 
used in a more individualized fashion, taking into account the clinical setting and therapeutic 
regmen, and treatment goals, which differ substantially among patients subsets, i.e. in 
younger and fit versus older patients with comorbidities.
A more challenging feature of the BCR pathway inhibitors is the fact that patients currently 
are treated continuously until disease progression or intolerable side effects occur. Current 
data are not mature yet to determine long-term tolerability of these medications, given that 
most patients have been treated for less than 5 years. Therefore, we have no robust 
experience about the occurrence of late effects, secondary malignancies, or Richter’s 
transformation as compared to chemo-immunotherapy.
Another issue related to long-term and potentially indefinite use of some of these new agents 
is the high costs that can burden our patients and the healthcare systems. This factor may 
limit the access of patients to some of these agents, especially in countries with limited/
restricted budgets for medical expenses. Indefinite kinase inhibitor therapy has become 
standard of care in patients with chronic myeloid leukemia, but it is foreseeable that the 
emergence of increasing numbers of new targeted cancer drugs will deplete the healthcare 
funds in the next few years, even in countries with less restrictive policies or well-funded 
healthcare systems. The hope therefore is that combination therapy approaches may 
eventually result in deep remissions that allow for drug discontinuation, and clinical trials 
with such an endpoint are currently under development. Furthermore, the competition of 
several new agents for a limited group of patients already has resulted in price negotiations 
and modifications to make these agents more affordable and available in some countries.
The broadening of the therapeutic armamentarium in CLL demands for the definition of 
specific criteria for choosing one drug over the other. In the absence of head-to-head 
comparisons derived from phase III studies, the side effect profile of the different drugs 
could guide the physician’s choice. For example, the bleeding risk is a factor usually taken 
into account in patients considered for ibrutinib treatment. The analysis of 327 patients from 
two trials of single agent ibrutinib showed that major bleeding events are generally 
uncommon and mostly occur in patients taking concomitantly one or more anticoagulants 
and/or antiplatelet agents[77]. Moreover, a recent report demonstrated that the risk of 
bleeding events is highest during the first weeks after initiation of treatment and decrease 
over time, and that patients who are at higher risk could be counseled to avoid antiplatelet 
agents[78]. Even if the requirement of antiplatelets or anticoagulant agents is not an absolute 
contraindication for ibrutinib treatment - which can be proposed to patients based on risk-
benefit considerations - due to the fact that patients with CLL are usually elderly and with 
comorbidities, attention should be posed to ibrutinib-related bleeding events, and monitoring 
of these patients should be implemented. Another AE that is often related to age and 
preexistent comorbidities in patients taking ibrutinib is atrial fibrillation. Regarding this side 
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effect, the recommendation is to monitor patients, with particular attention to the patients 
with a history of cardiac disease, especially atrial fibrillation.
The observation of characteristic treatment-emergent AE in patients treated with idelalisib, 
such as diarrhea/colitis, transaminitis and pneumonitis has led to the development of specific 
guidelines[79]. Although a definitive patho-mechanism for these AE has not been defined, 
preclinical and clinical data support an immune-mediated etiology. Therefore, particular 
attention in monitoring of these patients during treatment is necessary. A relevant factor that 
may also complicate the administration of both ibrutinib and idelalisib is their interference 
with drugs that are strong or moderate CYP3A inhibitors or inducers. Dose adjustment 
might be considered on an individual basis, based on risk-benefit considerations.
Regarding venetoclax, the occurrence of tumor lysis syndrome events has led to the 
implementation of a ramp-up dose increase with a strict monitoring of clinical and 
laboratory parameters, and IV fluid infusion is strongly recommended for patients who are 
at higher risk. These procedures impact the advantages in patient management related to the 
oral administration of the drug, and need to be taken into account when evaluating costs and 
practicability of this agent.
The analysis of treatment-emergent AE in patients treated with obinutuzumab has 
underlined a higher than expected rate of infusion-related reactions. These events are 
generally manageable and restricted to the first infusions of the drug, however they should 
not be underestimated given the elderly and comorbid population.
Combination trials which include new drugs are currently in development. Undoubtedly, the 
main questions to answer concern efficacy and tolerability, but also the cost issue will be 
critical. The durability of remissions in patients who achieve MRD-negative CR on regimen 
that include the new agents and who will have treatment discontinuation (versus continued 
kinase inhibitor therapy in control groups) will be explored. Among the different drug 
combinations that have been reported, ibrutinib and idelalisib enhance the efficacy of 
chemo-immunotherapy without significant added toxicity, but any added benefit from the 
chemo-immunotherapy backbone in these combinations has not been convincingly 
demonstrated, when compared to single-agent kinase inhibitor data. A longer follow-up and 
more mature data are needed to clarify whether the addiction of conventional chemotherapy 
drugs to BCR inhibitors will result in improved therapeutic results, maybe favoring MRD 
eradication. Venetoclax has high single-agent activity and synergy with various anti-cancer 
drugs in preclinical models of different B-cell malignancies[60], and preclinical studies 
support its combination with ibrutinib in CLL[80]. Despite the excellent results obtained 
with FCR, long-term remissions were achieved with chemo-immunotherapy only in lower-
risk CLL patients, for whom this remains an attractive therapy option. Moreover, it should 
be considered that the proportion of patients with CLL deemed adequately fit – considering 
age and comorbidities - to receive FCR treatment is relatively small. Moving forward, many 
CLL patients and the vast majority of high-risk CLL patients will transition to therapy with 
the newer agents, given their favorable safety and efficacy profile. Conversely, chemo-
immunotherapy will mostly be offered to younger low-risk patients who favor a limited 
duration of therapy and the prospect of long-term disease-free survival.
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Article highlights box
- Several new targeted agents were recently approved and are challenging 
established CLL treatment regimens
- The BTK inhibitor ibrutinib and PI3Kδ inhibitor idelalisib induce high 
overall response rates and durable remissions, which mostly are partial 
remissions
- The BCL-2 inhibitor venetoclax induces more complete remissions, but 
response durability is not yet well established
- At the approved dose, the anti-CD20 mAb obinutuzumab has higher 
efficacy than rituximab
- Disease eradication may become possible with combination therapy 
approaches of novel agents and/or with chemo-immunotherapy in low-risk 
CLL
- Longer follow-up is needed to fully characterize the spectrum of side effects 
of the novel agents
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Table 1
Novel targeted agents under study in CLL
Drug name Phase of development Route of
administration
Mechanism of action Target effects
Ibrutinib
(PCI-32765)
Approved (US and Europe) Oral Small molecule inhibitor of 
BTK
Inhibition of BCR signaling-
dependent
proliferation, survival, and 
microenviromnment
interactions.
Acalabrutinib
(ACP-196)
Phase III trials ongoing Oral Small molecule inhibitor of 
BTK
(second generation)
More potent and selective 
inhibition of BTK as
compared to ibrutinib.
Idelalisib
(GS-1101, CAL-101)
Approved (US and Europe) Oral Small molecule reversible 
inhibitor
of PI3K δ
Inhibition of BCR signaling-
dependent
proliferation, survival, and 
microenviromnment
interactions.
Duvelisib
(IPI-145)
Phase III trials ongoing Oral Small molecule inhibitor of 
PI3Kγ
and δ
Inhibition of BCR signaling in 
CLL cells and
inhibition of PI3K-dependent 
signaling in different
cellular components of adaptive 
and innate
immunity.
Venetoclax
(ABT-199, GDC-0199)
Phase III trials ongoing Oral Small molecule with BH3-
mometic
activity
Blocking of the BCL-2 anti-
apoptotic activity,
leading to programmed cell 
death.
Obinutuzumab
(GA101)
Approved (US and Europe) Intravenous Fully-humanized type II IgG1 
anti-
CD20 mAb, with a 
glycoengineered
Fc region
Induction of direct cell death and 
effector cell-
dependent cytotoxicity.
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